Disco Pharmaceuticals is pioneering a transformative approach to cancer treatment through its innovative surfaceome discovery technology. This technology allows for a comprehensive mapping of the cancer cell surface, enabling the identification of numerous new druggable targets that traditional methods, such as standard proteomics or genomic sequencing, cannot uncover. By focusing on surface-bound proteins and their communities, Disco Pharmaceuticals can generate detailed target information that enhances the design of highly specific large molecule therapeutics. This capability not only boosts the efficacy of treatments but also aims to reduce side effects, thereby improving patient care in oncology.

The company's research and development efforts are particularly focused on Small Cell Lung Cancer and microsatellite-stable Colorectal Cancer, with plans to explore additional tumor types. The scalable nature of their surfaceome discovery process accelerates the selection of novel molecular targets for both mono- and bi-specific antibodies, expediting the overall drug discovery timeline. With a team of experts from diverse backgrounds in academia, biotech, and pharmaceuticals, Disco Pharmaceuticals is well-positioned to leverage its breakthrough technology to advance targeted cancer therapies and ultimately transform cancer care.

Germany

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients. 

Disco Pharmaceuticals

Company Details